Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 117

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 117
---
obligations, the amount of funds in the Trust Account available for distribution to public stockholders may be reduced below $10.00 per
share.

Risks if the Adjournment Proposal
is Not Approved

If the Adjournment Proposal
is not approved, and an insufficient number of votes have been obtained to authorize the consummation of the Business Combination, our
board of directors will not have the ability to adjourn the Special Meeting to a later date in order to solicit further votes, and, therefore,
the Business Combination will not be approved, and, therefore, the Business Combination may not be consummated.

Our board of
directors is seeking approval to adjourn the Special Meeting to a later date or dates if, at the Special Meeting, based upon the tabulated
votes, there are insufficient votes to approve each of the Condition Precedent Proposals. If the Adjournment Proposal is not approved,
our board of directors will not have the ability to adjourn the Special Meeting to a later date and, therefore, will not have more time
to solicit votes to approve the Condition Precedent Proposals. In such events, the Business Combination would not be completed.

| 45 |

Risks Related to Longevity’s
Business

Unless the context
otherwise requires, throughout this subsection, references to “Longevity,” “Aegeria,” or “Cerevast,”
refer to Longevity, Aegeria and Cerevast prior to the consummation of the Business Combination, and references to “we,” “our”
and “us” refer to Longevity and the Targets together, which will be the business following the consummation of the Business
Combination.

We have a history of net
losses, and we expect to continue to incur losses for the foreseeable future. If we ever achieve profitability, we may not be able to
sustain it.

Each of the Targets
has incurred losses since their respective inception and expect to continue to incur losses for the foreseeable future. On a combined
basis, for the nine months ended September 30, 2024, the Targets have reported net losses of approximately $5.1 million in the aggregate
and had an accumulated deficit of approximately $40.6 million at September 30, 2024. We expect to continue to incur net losses for the
foreseeable future.

We will continue
to incur substantial expenses without corresponding revenues as we continue to test, develop and commercialize some of our